Background Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral arteries, the high in-stent restenosis rate (50-60%) in the femoropopliteal artery still remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation. Methods and Results A total of 141 consecutive patients scheduled for PTA in the femoropopliteal artery between September 1999 and April 2004 were retrospectively analyzed for the use of cilostazol. Target lesion revascularization (TLR) was defined as repeated PTA in patients who had a recurrence of symptoms with diameter stenosis >50% by angiography. Patient and lesion characteristics were similar between the cilostazol (+) and cilostazol (-) groups. Use of other medications was similar between the groups, except for ticlopidine, which was more frequently used in the cilostazol (-) than in the cilostazol (+) group (15% vs 61%, p<0.01). TLR was significantly reduced in the cilostazol (+) 
here has been an increasing trend in the number of elderly patients with peripheral artery disease who are unqualified for bypass surgery because of comorbidity. Currently, percutaneous transluminal angioplasty (PTA), a less invasive procedure than bypass surgery, is the most common alternative, particularly in patients with peripheral artery disease complicating coronary artery disease. However, the 1-year patency rate after PTA is low, particularly in the femoropopliteal artery (FPA), with a mean patency rate of 61%. [1] [2] [3] [4] [5] Target lesion revascularization (TLR) is required more frequently in the FPA than for the coronary arteries and hence, transcatheter treatment of the FPA is currently hampered by the high restenosis rate.
Although adjunctive therapy for PTA to prevent restenosis is desirable, efficacious agents have not been established. Cilostazol is a unique antiplatelet agent that causes vasodilatation and inhibits proliferation of vascular smooth muscle cells. [6] [7] [8] [9] [10] [11] [12] Cilostazol improves the walking distance in patients with intermittent claudication [13] [14] [15] [16] [17] and significantly reduces restenosis and TLR after successful percutaneous coronary intervention. [18] [19] [20] [21] [22] [23] [24] [25] Nonetheless, the efficacy of cilostazol as an adjunctive therapy after PTA in the FPA is unclear, so we undertook to investigate this issue.
Methods

Patients
The records of a total of 141 consecutive patients with symptomatic peripheral artery disease scheduled for PTA or/and stenting in the FPA at Kansai Rosai Hospital during the period of September 1999-April 2004 were retrospectively studied regarding the use of cilostazol and TLR. This study was approved by the ethics committee of Kansa Rosai Hospital and each patient gave informed consent.
PTA Procedure
PTA was performed from the ipsilateral femoral artery with an antegrade approach (n=66, 47%). Cross-over approach from the contralateral femoral artery was chosen if the lesion was close to the ipsilateral access site (n=34, 24%). In patients with a long lesion length (>15 cm) a bidirectional technique was used, using both an antegrade approach from the brachial artery and a retrograde approach from the popliteal artery, while the patient was prone.
All patients were given 5,000 units of heparin by intraarterial injection prior to initial balloon angioplasty. A selfexpandable Easy Wallstent (Boston Co, Ltd) was subsequently implanted if the lesions showed either flow-limiting dissections, a diameter stenosis >30%, or failure to establish initial patency. Successful PTA was defined as diameter stenosis <30% with the relief of symptoms.
Four patients died during the study period. Patients with poor adherence to the medication regimen during the study period were also excluded from the analysis (n=16). 
Medications
At least 2 antiplatelet and anticoagulant drugs were pre-and postoperatively prescribed for each patient by the attending physicians and were continued after the intervention.
Outcomes
Outcomes were analyzed by using a clinical symptom score according to the criteria of Fontaine, the anklebrachial pressure index (ABPI), and TLR. Only patients complaining of symptoms were referred for follow-up angiography. TLR was performed for symptomatic lesions with a diameter stenosis >50%.
Statistical Analysis
Data are shown as mean ± standard deviation (SD). The unpaired t-test was used to compare continuous variables between the groups. The chi-square test or Fisher's exact test was used to compare ratios. Statistical significance was defined as a p<0.05.
Results
Patient and lesion characteristics did not differ between the cilostazol (+) and cilostazol (-) groups (Tables 1,2) .
Intervention procedures were similar between the groups as shown by the number of stents used, the incidence of stenting, and the post-PTA vascular diameter (Table 3) . TLR was significantly reduced in the cilostazol (+) group (Fig 1) . Use of additional medications was similar between the groups, except that ticlopidine was used more frequently in IIDA O et al.
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the cilostazol (-) than in cilostazol (+) group (Table 4) . Acute reclosure or subacute thrombosis during the 2 weeks immediately after PTA was not observed in either group. During the study period, the ABPI and symptoms based on the Fontaine criteria tend to be higher and lower, respectively, in the cilostazol (+) and cilostazol (-) groups, though there were no significant difference (Table 5) .
Discussion
This retrospective study of 141 consecutive patients suggests that cilostazol reduces TLR after PTA in the FPA and showed no difference between the cilostazol (+) and cilostazol (-) groups in the use of additional medication, except that ticlopidine hydrochloride was more frequently used in the cilostazol (-) group. During the study period, the TLR ratio was significantly lower in the cilostazol (+) group. Thus, administration of cilostazol after PTA in the FPA may reduce the incidence of restenosis.
The present study is the first to suggest the efficacy of cilostazol for preventing restenosis of the FPA after PTA, although inhibition of smooth muscle cell proliferation has been shown in the rat carotid artery 12 and canine external iliac artery after stent placement. 26 Tsuchikane et al 18, 22 and Sekiguchi et al 27 have reported that restenosis after coronary artery intervention was attenuated by cilostazol.
Cilostazol has antiplatelet aggregation and vasodilatory effects by selectively inhibiting the phosphodiesterase type 3 activity of platelets and vascular smooth muscle cells. [28] [29] [30] In addition, inhibition of vascular smooth muscle cell proliferation has also been reported. 11, 12 Inhibition of smooth muscle cell proliferation and the vasodilatory effects are unique features of cilostazol that other antiplatelet drugs do not possess and may contribute to the reduction in TLR after PTA in the clinical setting. The vasodilator effect is also considered responsible for the improvement in the walking distance of patients with peripheral artery disease, [13] [14] [15] [16] [17] presumably because the improved blood flow relieves the symptoms in the lower limb. In addition, functional improvement, protective effects, and growth acceleration in the endothelial cells associated with administration of cilostazol have been reported in animals and humans. [31] [32] [33] [34] [35] [36] [37] [38] Based on these findings, the following mechanisms that explain the reduction in TLR in the cilostazol (+) group can be considered.
1. Improved blood flow in the lower limb, produced by the strong vasodilatory effect as a result of the effect on vascular smooth muscle cells. 2. Proliferation of the regenerated inner membrane at the treatment site is inhibited as a consequence of the inhibitory effect on the proliferation of vascular smooth muscle cells, which results in less restenosis and TLR. 3. Improved endothelial function and vasodilation contribute to the improvement of the pathology of arteriosclerosis obliterans (ASO), resulting in reduction in TLR. Matsui et al report increased vascular endothelial growth factor and macrophage colony-stimulating factor in ASO patients. 39 The changes in the levels of these cytokines before and after PTA and by cilostazol administration should be examined among ASO patients in the future.
Study Limitations
Follow-up angiography was not performed in all cases, only in those patients who had recurrence of symptoms. Patients who had angiographic restenosis without recurrence of symptoms may have been overlooked. Nonetheless, these patients have less morbidity in the clinical setting. This study was a nonrandomized, retrospective, and single- center trial. A large-scale, prospective, multicenter study should be undertaken to verify these tentative conclusions.
